<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01392586</url>
  </required_header>
  <id_info>
    <org_study_id>BOOG 2010-05</org_study_id>
    <nct_id>NCT01392586</nct_id>
  </id_info>
  <brief_title>Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer</brief_title>
  <acronym>SUBMIT</acronym>
  <official_title>Systemic Therapy With or Without Up Front Surgery of the Primary Tumor in Breast Cancer Patients With Distant Metastases at Initial presenTation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeroen Bosch Ziekenhuis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Borstkanker Onderzoek Groep</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Comprehensive Cancer Centre The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jeroen Bosch Ziekenhuis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SUBMIT is a clinical trial that intends to answer the question whether up front breast
      surgery in patients with primary distant metastatic breast cancer will result in an
      improvement of the 2-year survival compared to the survival achieved with systemic therapy
      and delayed local treatment or systemic therapy alone.

      Randomization will take place immediately after the diagnosis of primary distant metastatic
      breast cancer. Patients either randomize for up front surgery of the breast tumor (UFS)
      followed by systemic therapy or for systemic therapy (ST) potentially followed by delayed
      local treatment of the breast tumor.

      The primary endpoint of this trial is the 2-years survival. Quality of life is one of the
      most important secondary endpoints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Netherlands approximately one out of eight women will be diagnosed with breast cancer;
      5% have metastatic disease at presentation. Because metastatic breast cancer is considered to
      be an incurable disease, it is only treated with a palliative intent. Recent retrospective
      studies have demonstrated that (complete) resection of the primary tumor significantly
      improves the outcome of patients with primary metastatic breast cancer. However, other
      studies showed that the survival benefit in patients who underwent surgery is caused by
      selection bias.

      SUBMIT is a clinical trial that intends to answer the question whether up front breast
      surgery in patients with primary distant metastatic breast cancer will result in an
      improvement of the 2-year survival compared to the survival achieved with systemic therapy
      and delayed local treatment or systemic therapy alone.

      Patients to submit in this study are patients with primary distant metastatic breast cancer,
      with no prior treatment of the breast cancer, who are 18 years or older and fit enough to
      undergo surgery and systemic therapy. Exclusion criteria are: history of breast cancer, other
      malignancy within the last 10 years, surgical treatment or radiotherapy of this breast tumor
      before randomization, irresectable T4 tumor or synchronous bilateral breastcancer.

      Randomization will take place immediately after the diagnosis of primary distant metastatic
      breast cancer. Patients either randomize for up front surgery of the breast tumor (UFS)
      followed by systemic therapy or for systemic therapy (ST) potentially followed by delayed
      local treatment of the breast tumor.

      The primary endpoint of this trial is the 2-years survival. Quality of life is one of the
      most important secondary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to low accrual rate
  </why_stopped>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>participants will be followed until death (expected median survival 31 months for surgery group)</time_frame>
    <description>Survival is defined in months from the time of randomization until death. Overall survival will be expressed as the median survival in months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>5 years after randomisation</time_frame>
    <description>The EORTC QLQ - C30 and BR23 questionnaires will be used for the measurement of the quality of life. The quality of life will be assessed at 3, 6, 12, 18 months and 2,3,4,5 years after randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two year survival</measure>
    <time_frame>2 yrs after randomisation</time_frame>
    <description>The percentage of patients who survive two years after randomization will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unplanned local therapies</measure>
    <time_frame>5-6 months after randomisation</time_frame>
    <description>The number of patients who will receive local treatment at another point than scheduled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in systemic therapy given</measure>
    <time_frame>6 months after randomisation</time_frame>
    <description>register which patients receive what treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of pathological resection margin</measure>
    <time_frame>Pathological report approximately 1 day after surgery</time_frame>
    <description>The definition of a complete resection in this trial means free resection margins for the invasive component.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatments of the axillary lymph nodes</measure>
    <time_frame>6 months after randomisation</time_frame>
    <description>register which patients receive these treatments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Upfront surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upfront surgery followed by systemic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Systemic therapy possibly followed by local treatment of the breast tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>upfront breast surgery</intervention_name>
    <description>surgery of primary tumor, lumpectomy or mastectomy</description>
    <arm_group_label>Upfront surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>systemic therapy</intervention_name>
    <description>chemotherapy, immunotherapy or endocrine therapy (possibly followed by local surgery of the breast)</description>
    <arm_group_label>Systemic therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed primary distant metastatic breast cancer (M1)

          -  Anticipated survival of at least 6 months

          -  Histologically proven breast cancer

          -  Hormonal and HER2Neu status should be known

          -  T1-T3, resectable T4 status, N0-N3

          -  Performance status of the patient should allow surgery / systemic therapy

          -  Co-morbidity of the patient should allow surgery / systemic therapy

          -  Age &gt; 18 years

          -  Written informed consent

        Exclusion Criteria:

          -  Primary invasive breast cancer in medical history

          -  Other malignancy within the last 10 years, besides basal cell carcinoma of the skin or
             early stage cervical cancer

          -  Surgical treatment / radiotherapy of this breast tumor before randomization

          -  Irresectable T4 breast tumor

          -  Synchronous bilateral breast cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M.F. Ernst, dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jeroen Bosch Ziekenhuis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A.C. Voogd, dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>V.C.G. Tjan-Heijnen, Prof, dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelmina Ziekenhuis</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rode Kruis Ziekenhuis</name>
      <address>
        <city>Beverwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tergooiziekenhuizen, loc Blaricum</name>
      <address>
        <city>Blaricum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Ziekenhuis, Loc. Leijweg</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Bronovo</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Elkerliek, loc Helmond</name>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente, Loc. SMT</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Ziekenhuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis, Loc. Nieuwegein</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikazia Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orbis Medisch Centrum</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viecuri Medisch Centrum, loc. St Maartens Gasthuis</name>
      <address>
        <city>Venlo</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2011</study_first_submitted>
  <study_first_submitted_qc>July 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2011</study_first_posted>
  <last_update_submitted>February 2, 2014</last_update_submitted>
  <last_update_submitted_qc>February 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jeroen Bosch Ziekenhuis</investigator_affiliation>
    <investigator_full_name>M.F. Ernst, dr</investigator_full_name>
    <investigator_title>Dr.M.F.Ernst</investigator_title>
  </responsible_party>
  <keyword>survival</keyword>
  <keyword>systemic therapy</keyword>
  <keyword>upfront surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

